Opinion statement
-
In the past decade, advances in molecular genetics have shown that many familial neuromuscular and cardiovascular diseases share a common pathophysiology. They are caused by inherited mutations in the cellular cytoskeleton of cardiac and skeletal muscle cells. The clinical manifestation of cardiac disease in neuromuscular disorders is common and their management should include both periodic cardiac assessment and appropriate symptomatic and definitive therapy.
-
Dilated cardiomyopathy is a common complication of neuromuscular diseases. Cardiac function may decline progressively as part of the natural history of the disease, but current medical therapy, including angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics, can be used to alleviate symptoms of left ventricular dysfunction.
-
Conduction disturbances may be an important cause of mortality, especially in patients with Emery Dreifuss muscular dystrophy, Kearns-Sayre syndrome, and myotonic dystrophy, and thus pacemaker implantation can be life-saving. Rhythm disturbances, such as atrial fibrillation and ventricular tachyarrhythmias, have been reported in patients with neuromuscular diseases. Treatment is based on preventing sudden death and embolic phenomena and cardioverting or controlling atrial fibrillation. In these patients, problems may arise with anticoagulation and antiarrhythmic therapy due to the inherent locomotor instability associated with the disease, and the presence of concomitant atrioventricular disease.
-
Although uncommon, hypertrophic cardiomyopathy may be a feature of some neuromuscular disorders. Patients should undergo regular risk stratification for sudden cardiac death and symptoms such as heart failure can be treated with medical therapy.
Similar content being viewed by others
References and Recommended Reading
Ohlendieck K: Towards an understanding of the dystrophin-glycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibres. Eur J Cell Biol 1996, 69:1–10.
Towbin JA: The role of the cytoskeleton proteins in cardiomyopathies. Curr Opin Cell Biol 1998, 10:131–139.
Towbin JA, Hejtmancik F, Brink P, et al.: X-Linked cardiomyopathy (XLCM): molecular evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993, 87:1854–1865.
Muntoni F, Cau M, Ganau A, et al.: Deletion of the dystrophin muscle promotor region associated with X-Linked dilated cardiomyopathy. N Engl J Med 1993, 329:921–925.
Badorff C, Lee GH, Lamphear BJ, et al.: Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999, 5:320–326. A recent important paper providing in vivo evidence of the link between viral infection and a cellular model of the disease.
Bione S, Maestrini E, Rivella S, et al.: Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994, 8:323–327.
van der Kooi AJ, van Meegan M, Ledderhof TM, et al.: Genetic localization of a newly recognized autosomal dominant limb-girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet 1997, 60:891–895.
Fatkin D, Mcrea C, Sasaki T, et al.: Missense mutations in the rod domain of the lamin A/C gene causes dilated cardiomyopathy and conduction system disease. N Engl J Med 1999, 341:1715–1724.
Kunkel LM: Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 1986, 322:73–77.
Silverman L, Mendell J, Sahenk Z: Significance of creatine phosphokinase isoenzymes in Duchenne muscular dystrophy. Neurology 1967, 26:561–564.
Slucka C: The electrocardiogram in Duchenne’s progressive muscular dystrophy. Circulation 1968, 38:933–940.
Nigro G, Comi LI, Politano L, et al.: The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990, 26:271–277.
Perloff JK: Cardiac rhythm and conduction in Duchenne’s muscular dystrophy. J Am Coll Cardiol 1984, 3:1263–1267.
Sanyal SK, Johnson WW, Dische MR, et al.: Dystrophic degeneration of papillary muscle and ventricular myocardium: a structural basis for mitral valve prolapse in Duchenne’s muscular dystrophy. Circulation 1980, 62:430–439.
Wakai S, Minami R, Kameda K, et al.: Electron microscopic study of the biopsied cardiac muscle in Duchenne’s muscular dystrophy. J Neurol Sci 1988, 84:167–176.
Boland BJ, Silbert PL, Groover RV, et al.: Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediat Neurol 1996, 14:7–12.
Lane RJM, Gardener-Medwin D, Roses AD: Electrocardiographic abnormalities in carriers of Duchenne muscular dystrophy. Neurology 1980, 30:499–501.
Grain L, Cortina-Borja M, Forfar C, et al.: Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. Nuromusc Disord 2001, 11:186–191. Clinically important paper that provides prevalence data of cardiac complications in carrier females, that appears less than previously reported.
Norman AM, Thomas NST, Kingston HM, et al.: Becker muscular dystrophy: correlation of deletion type with clinical severity. J Med Genet 1990, 27:236–239.
Hoffman EP, Brown RH Jr, Kunkel LM: The protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919–928.
Monaco AP, Bertelson CJ, Liechti-Gallati S, et al.: An explanation for phenotypic differences between patients bearing partial deletions of DMD locus. Genomics 1988, 2:90–95.
Nigro G, Comi LI, Limongelli FM, et al.: Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve 1983, 6:253–262.
Ortiz-Lopez R, Li H, Su J, et al.: Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation 1997, 95:2434–2440.
Bione S, Maestrini E, Rivella S, et al.: Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994, 8:323–327.
Emery AEH: Emery-Dreifuss muscular dystrophy and other related disorders. Br Med Bull 1989, 45:772–787.
Merlini L, Granata C, Dominici P, et al.: Emery-Dreifuss muscular dystrophy: report of five cases in a family and review of the literature. Muscle Nerve 1986, 9:481–485.
Voit T, Krogmann O, Lenard HG, et al.: Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropaediatrics 1988, 19:62–71.
Cartegni L, Raffaele di Barletta M, Barresi R, et al.: Heart specific localzation of emerin: new insights into Emery-Dreifuss muscular dystrophy. Hum Mol Genet 1997, 6:2257–2264.
Bensaid J, Vallat JM, Ansallam D, et al.: Total permanent auricular paralysis. Review of the literature apropos 109 cases [in French]. Ann Cardiol Angeiol 1995, 44:139–145.
Bonne G, Di Barletta MR, Varnous S, et al.: Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999, 21:285–288.
Bushby KMD, Beckmann JS: Diagnostic criteria for the limb-girdle muscular dystrophies: report of the 30th ENMC workshop on limb-girdle muscular dystrophies. Neuromusc Disord 1995, 5:71–74.
McNally EM, Passos Bueno MR, Bonnemann C, et al.: Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 1996, 59:1040–1047.
Nigro V, Comi LI, Politano L: Clinical and genetic aspects of sarcoglycanopathies. Acta Myol 1999, 3:51–53.
Ben Hamida M, Ben Hamida C, Zouari M, et al.: Limb-girdle muscular dystrophy 2C: clinical aspects. Neuromuscul Disord 1996, 6:493–494.
Politano L, Nigro V, Passamano L, et al.: Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001, 11:178–185.
Dalakas MC, Park KY, Semino-Mora C, et al.: Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000, 342:770–780.
Amato AA, Kagan-Hallet K, Jackson CE, et al.: The wide spectrum of myofibrillar myopathy suggests a multifactorial etiology and pathogenesis. Neurology 1998, 51:1646–1655.
Goebel HH: Desmin-related myopathies. Curr Opin Neurol 1997, 10:426–429.
Milner DJ, Weitzer G, Tran D, et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 1996, 134:1255–1270.
Goldfarb LG, Park KY, Cervenakova L, et al.: Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998, 4:402–403.
Mahadevan M, Tsilfidis C, Sabourin L, et al.: Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992, 255:1253–1255.
Boucher CA, King SK, Carcy N, et al.: A novel homeodomain-encoding gene is associated with a large CpG island interrupted by the myotonic dystrophy unstable (CTG)n repeat. Hum Mol Genet 1995, 10:1919–1925.
Melacini P, Villanova C, Menegazzo E, et al.: Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. J Am Coll Cardiol 1995, 25:239–245.
Fragola PV, Luzi M, Calo L, et al.: Cardiac involvement in myotonic dystrophy. Am J Cardiol 1994, 74:1070–1072.
Hawley R, Milner M, Gottdeiner JS: Myotonic heart disease: a clinical follow-up. Neurology 1991, 41:259–262.
Motta J, Guilleminault C, Billingham M: Cardiac abnormalities in myotonic dystrophy. Electrophysiologic and histopathologic studies. Am J Med 1979, 67:467–473.
Badano L, Autoro C, Fragola P: Left ventricular myocardial function in myotonic dystrophy. Am J Cardiol 1993, 71:987–991.
Child JS, Perloff JK: Myocardial myotonia in myotonic muscular dystrophy. Am Heart J 1995, 129:982–990.
Ozawa T, Tanaka M, Sugiyama S, et al.: Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy. Biocem Biophys Res Commun 1990, 170:830–836.
Zeviani M, Moraes CT, DiMauro S, et al.: Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988, 38:1339–1346.
Gallastegui J, Hariman RJ, Handler B, et al.: Cardiac involvement in the Kearns-Sayre syndrome. Am J Cardiol 1987, 60:385–388.
Ito T, Hattori K, Tanaka M, et al.: Mitochondrial cytopathy. Jpn Circ J 1990, 54:1214–1220.
Yoneda M, Tanaka M, Nishikimi M, et al.: Pleiotropic molecular defects in energy-transducing complex in mitochondrial encephalomyopathy (MELAS). J Neurol Sci 1989, 92:143–158.
Okajima Y, Tanabe Y, Takayanagi M, et al.: A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Heart 1998, 80:292–295.
Sato W, Tanaka M, Sugaiyama S, et al.: Cardiomyopathy and angiopathy in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Am Heart J 1994, 128:733–741.
Seibel P, Degoul F, Bonne G, et al.: Genetic biochemical and pathophysiological characterization of a familial mitochondrial encephalomyopathy (MERRF). J Neurol Sci 1991, 105:217–224.
Fukuhara N, Tokiguchi S, Shirakawa K, et al.: Myoclonus epilepsy associated with ragged-red fibers: disease entity or a syndrome? Light and electronmicroscopic studies of two cases and review of the literature. J Neurol Sci 1980, 47:117–133.
Smeitink J, van del Heuvel L: Human mitochondrial complex I in health and disease. Am J Hum Genet 1999, 64:1505–1510.
Chamberlain S, Shaw J, Rowland A, et al.: Mapping of mutation causing Friedreich’s ataxia to human chromosome 9. Nature 1988, 334:248–250.
Campuzano V, Montermini L, Molto MD, et al.: Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423–1427.
Koutnikova H, Campuzano V, Foury F, et al.: Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 1997, 16:345–351.
Harding AE: Friedriechs ataxia. Brain 1981, 104:589–620.
Pentland B, Fox KAA: The heart in Friedriechs ataxia. J Neurol Neurosurg Psychiatry 1983, 46:1138–1142.
Dutka DP, Donnelley JE, Palka P, et al.: Echocardiographic characterization of cardiomyopathy in Friedreich’s ataxia with tissue Doppler echocardiographically derived myocardial velocity gradients. Circulation 2000, 102:1276–1282. A prospective study characterizing echocardiographic changes in Friedreich’s ataxia and their relationship to the genetic abnormalities in the frataxin gene.
Isnard R, Kalotka H, Durr A, et al.: Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich’s ataxia. Circulation 1997, 95:2247–2249.
Durr A, Cossee M, Agid Y, et al.: Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 1996, 335:1169–1175.
The heart in myotonic dystrophy [editorial]. Lancet 1992, 339:528–529.
Mudge B, Taylor PB, Vanderspek AFL: Perioperative hazards in myotonic dystrophy. Anesthesia 1980, 35:492–495.
Berenberg RA, Pellock JM, DiMauro S, et al.: Lumping or splitting? ‘Ophthalmoplegia-plus’ or Kearns-Sayre syndrome? Ann Neurol 1977, 1:37–54.
Hewer RL: Study of fatal cases of Friedriechs ataxia. Br Med J 1968, 3:639–652.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sachdev, B., Elliott, P.M. & McKenna, W.J. Cardiovascular complications of neuromuscular disorders. Curr Treat Options Cardio Med 4, 171–179 (2002). https://doi.org/10.1007/s11936-002-0037-x
Issue Date:
DOI: https://doi.org/10.1007/s11936-002-0037-x